公司概覽
業務類別 Diagnostics & Research
業務概覽 Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ inthe office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
公司地址 One IDEXX Drive, Westbrook, ME, USA, 04092
電話號碼 +1 207 556-0300
傳真號碼 +1 207 556-4346
公司網頁 https://www.idexx.com
員工數量 11000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Michael G. Erickson, PhD Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine -- 13/01/2026
Mr. Andrew J. Emerson Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer 美元 531.15K 27/03/2026
Mr. George J. Fennell Executive Vice President, Global CAG Commercial -- 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 美元 1.15M 13/01/2026
Dr. Martin Alexander Smith, PhD Executive Vice President, Global Operations and Research and Development 美元 594.05K 27/03/2026
Ms. Sharon E. Underberg Executive Vice President, General Counsel and Corporate Secretary -- 27/03/2026
Mr. Michael J. Lane Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology 美元 594.05K 27/03/2026
Mr. Michael Schreck Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience -- 27/03/2026
Mr. Michael P. Johnson Senior Vice President and Chief Human Resources Officer -- 27/03/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce L. Claflin Independent Director 27/03/2026
Mr. Daniel M. Junius Independent Director 27/03/2026
Ms. M. Anne Szostak Independent Director 13/02/2026
Mr. Lawrence D. Kingsley Non-Executive Chairman of the Board 27/03/2026
Dr. Sophie V. Vandebroek, PhD Independent Director 27/03/2026
Mr. Stuart M. Essig, PhD Independent Director 27/03/2026
Mr. Jonathan J. Mazelsky Director, President and Chief Executive Officer 13/01/2026
Mr. Sam A. Samad Independent Director 27/03/2026
Mr. Joseph L. Hooley Lead Independent Director 27/03/2026
Ms. Karen A. Peacock Independent Director 27/03/2026
Ms. Irene Chang Britt Independent Director 27/03/2026
 
所屬ETF (更新日期: 02/05/2026 04:29)
代號 名稱 佔比% 持有日期
DUHPDimensional US High Profitability ETF0.13%29/04/2026
ITOTiShares Core S&P Total US Stock Mkt ETF0.13%29/04/2026
VVVanguard Large-Cap ETF0.12%31/03/2026
SCHXSchwab US Large-Cap ETF™0.11%29/04/2026
GSLCGoldman Sachs ActiveBeta® US LgCp Eq ETF0.10%29/04/2026
IUSGiShares Core S&P US Growth ETF0.09%29/04/2026
MTUMiShares MSCI USA Momentum Factor ETF0.08%29/04/2026
VTVanguard Total World Stock ETF0.08%31/03/2026
SPMOInvesco S&P 500® Momentum ETF0.08%29/04/2026
DFACDimensional US Core Equity 2 ETF0.08%29/04/2026
VOOGVanguard S&P 500 Growth ETF0.07%31/03/2026
IWBiShares Russell 1000 ETF0.07%29/04/2026
QQEWFirst Trust Nasdaq-100 Sel Eql Wght ETF0.07%29/04/2026
TQQQProShares UltraPro QQQ0.06%29/04/2026
QQQINEOS Nasdaq-100(R) High Income ETF0.06%29/04/2026
SCHBSchwab US Broad Market ETF™0.06%29/04/2026
IYHiShares US Healthcare ETF0.05%29/04/2026
PWBInvesco Large Cap Growth ETF0.05%29/04/2026
IXJiShares Global Healthcare ETF0.05%28/04/2026
JQUAJPMorgan US Quality Factor ETF0.05%29/04/2026
  1   2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.